医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Acquires the iPS Cell Business Unit of Stemgent, Inc.

2014年09月09日 PM09:30
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

ReproCELL (JASDAQ:4978) announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. This acquisition allows the ReproCELL Group to expand the product lineups of its iPS Cell Business and establish technical advantages, promoting great differentiation.

Stemgent has succeeded in launching many worldwide leading iPS cell research reagent products including mRNA reprogramming kit, xeno-free culture media, and specialty chemicals for cell differentiation, and has established a world-famous, proven and trusted brand in the iPS cell field. Through the acquisition, ReproCELL Group can offer a wide variety of products with full coverage of iPS cell technologies, while also strengthening its sales channel and marketing function in the United States. In addition, the iPS Cell Business Unit of Stemgent has a broad network of academic researchers including a strong scientific advisory board in the United States, while ReproCELL has a wide academic network in Japan with a strong scientific advisory board, as well as its founder Prof. Nakatsuji at Kyoto University and Prof. Nakauchi at the University of Tokyo. The strongest academic network combined in United States and Japan will give us sustainable technical advantages in the iPS cell field.

(Reference)
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world’s first human iPS cell products in 2009 and with the world’s most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK) and BioServe (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.

Stemgent, Inc.
Stemgent is engaged in working alongside some of the world’s leading iPS cell scientists in developing innovative technology and application solutions for the advancement of iPS cell research. Its mission is to help simplify and support cellular reprogramming research by producing products being designed by leading iPS cell researchers worldwide.

(URL)
ReproCELL: https://www.reprocell.com/en/
Reinnervate: http://reinnervate.com/
BioServe: http://www.bioserve.com/
Stemgent: https://www.stemgent.com/

CONTACT

ReproCELL, Inc.
Chikafumi Yokoyama, +81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc